The Food and Drug Administration has approved the first drug designed to reduce how often people with a rare blood cancer need blood removed from their bodies. On August 28 the agency cleared Mimrylo, known generically as rusfertide, for the treatment of erythrocytosis in adults with polycythemia vera.
Polycythemia vera causes bone marrow to produce too many red blood cells. The excess thickens the blood and raises the risk of clots, stroke, and heart attack. The condition affects roughly 90,000 people in the United States, and for decades the cornerstone of management has been therapeutic phlebotomy, the scheduled removal of blood to keep hematocrit below 45 percent.
For patients and the family members who drive them to appointments, that has meant a recurring cycle of infusion center visits, needle sticks and lost work hours stretching across years. Tanya Wroblewski, director of the Division of Nonmalignant Hematology within the FDA's Center for Drug Evaluation and Research, named that burden directly.
"People living with polycythemia vera have long faced the challenge of managing a chronic blood disorder with frequent blood draws to help address the consequences of the red blood cell overproduction," Wroblewski said, calling the approval a first-in-class option with the potential to meaningfully reduce patient burden.
A Different Target Inside the Iron Pathway
Mimrylo is the first approved treatment for polycythemia vera that mimics hepcidin, the hormone that regulates iron in the body. By restricting how much iron is available, the drug limits the raw material the marrow needs to overproduce red blood cells. Treatment starts at 19 mg given once weekly as a subcutaneous injection, then is adjusted to hold hematocrit below 45 percent.
That is a departure from the existing toolkit, which combines phlebotomy, low-dose aspirin and cytoreductive drugs such as hydroxyurea, interferon and ruxolitinib. Rather than removing red cells after they are made, the new approach constrains production upstream.
The approval rests on the Phase 3 VERIFY study, a global, randomized, double-blind, placebo-controlled trial in 293 adults with polycythemia vera who still needed frequent phlebotomies despite standard care. Efficacy was measured by the proportion of patients who did not meet criteria for phlebotomy between weeks 20 and 32. Overall, 76.9 percent of patients on Mimrylo required no phlebotomies during the 32-week period, compared with 32.9 percent on placebo. The most common adverse reactions were injection site reactions and anemia. The approval was granted to Takeda Pharmaceuticals America under priority review.
Evidence Boundaries Worth Naming Early
The trial measured hematocrit control and phlebotomy avoidance. It was not designed to show that the drug prevents strokes, heart attacks or deaths, and no such claim appears in the FDA announcement. Keeping hematocrit below 45 percent is a well-established treatment goal precisely because it is associated with lower cardiovascular risk, but this approval does not by itself establish that this drug reduces those events.
The drug was studied as an addition to standard care rather than a replacement for it, so patients should not expect aspirin or an existing cytoreductive therapy to be stopped automatically. Anemia appearing among the most common adverse reactions is a reminder that a treatment which restricts iron availability needs monitoring rather than a set-and-forget prescription. The prescribing information also flags new or worsening thrombocytosis, with instructions to check blood counts every two to four weeks after starting and during dose changes.
Financial context belongs in the record too. Rusfertide was discovered by Protagonist Therapeutics, which led development through Phase 3, and Takeda holds global commercialization rights under a 2024 licensing agreement. Approval triggers $275 million in payments to Protagonist plus tiered royalties. The VERIFY study was funded by the companies that make and sell the drug. That does not invalidate results the FDA reviewed independently, but readers weighing a first-in-class launch should know who paid for the evidence.
The Households Most Likely to Notice a Change
The people who stand to gain most are patients whose disease has not been adequately controlled by existing therapies and who are phlebotomy-dependent, meaning they need repeated blood removal to stay at target. Those are often the patients making the most trips to a hospital or infusion center.
Older adults and people in rural areas carry the heaviest logistical load, because scheduled phlebotomy requires reliable transportation and a facility that can perform it. A weekly injection at home changes that calculation, though it introduces a different demand in the form of consistent self-administration and refill management.
Teresa Bitetti, president of Takeda's global oncology business unit, told Reuters the drug would reach patients within 48 hours of approval, and said the company would price it in a way that is fair to the value while ensuring access. No list price was disclosed at launch. Availability is not the same as affordability. Coverage decisions by Medicare Part D plans and commercial insurers, prior authorization requirements, and specialty pharmacy routing will determine what patients actually pay, and none of that is settled yet.
Questions for a Hematologist Before Anything Changes
No one with polycythemia vera should stop phlebotomy, aspirin, or a cytoreductive drug based on a news story. Treatment decisions in a myeloproliferative neoplasm belong with a hematologist who knows the individual's clot history, hematocrit trend, and symptom burden.
Patients who want to raise the option can ask whether their hematocrit control meets the target, how many phlebotomies they have needed in the past year, and whether a hepcidin-mimicking drug fits their disease pattern. It is reasonable to ask what monitoring for anemia, iron status, and platelet counts would involve, and whether the drug would be added to or substituted for part of the current regimen.
On cost, patients can ask the prescribing office to run a benefits check before the first fill, ask about manufacturer support programs, and confirm whether a specialty pharmacy is required. Anyone with polycythemia vera who develops sudden chest pain, one-sided weakness, speech difficulty, vision loss, or new leg swelling should seek emergency care, since those can signal a clot.
What remains unknown is long-term safety beyond the trial period, whether the drug reduces cardiovascular events, how payers will handle coverage, and what real-world pricing will look like. An open-label extension of VERIFY is ongoing.
Key Questions Answered
What did the FDA approve? Mimrylo, generically rusfertide, for the treatment of erythrocytosis in adults with polycythemia vera. It is the first approved treatment for the condition that mimics hepcidin, the body's iron-regulating hormone.
What is polycythemia vera? A rare, chronic blood cancer in which bone marrow overproduces red blood cells. The thickened blood raises the risk of clots, stroke, and heart attack. It affects roughly 90,000 people in the United States.
How is it currently treated? With therapeutic phlebotomy, low-dose aspirin, and cytoreductive drugs, aimed at keeping hematocrit below 45 percent. Phlebotomy has been a cornerstone of treatment for decades.
What did the trial show? In the Phase 3 VERIFY study of 293 patients, 76.9 percent of those on the drug required no phlebotomies during the 32-week period, compared with 32.9 percent on placebo. The drug was added to standard care.
Does the drug prevent strokes or heart attacks? That was not what the trial was designed to show. It measured hematocrit control and phlebotomy avoidance. Lower hematocrit is associated with reduced cardiovascular risk, but the approval does not establish that this drug reduces those events.
Who funded the research? Protagonist Therapeutics discovered the drug and led development through Phase 3, and Takeda holds global commercialization rights. The VERIFY study was company-funded.
